Mabwell secures Brazilian ANVISA GMP approval for denosumab biosimilar, enabling market entry in Latin America’s largest pharmaceutical economy
Executive summary: Mabwell’s wholly-owned subsidiary T-mab successfully passed a Brazilian GMP inspection by ANVISA for its denosumab injections, achieving PIC/S GMP certification as announced on August 9, 2026. This approval is a prerequisite for marketing denosumab biosimilars in Brazil, the largest pharmaceutical market in Latin America, and enables Mabwell to compete with branded biologics in osteoporosis and oncology indications.
Who is involved: Mabwell (688062.SH, 02493.HK), its subsidiary T-mab, and Brazil’s Health Regulatory Agency (ANVISA).
Likely next: Mabwell will proceed with ANVISA product registration for denosumab, followed by potential launch in Brazil and possible expansion to other LATAM markets recognizing PIC/S standards.
Mabwell’s subsidiary T-mab has passed a Brazilian Health Regulatory Agency (ANVISA) inspection for its denosumab injections, achieving PIC/S GMP certification. This approval validates the manufacturing quality of Mabwell’s biosimilar to Amgen’s Prolia/Xgeva, clearing a critical regulatory hurdle for commercialization in Brazil. The move supports Mabwell’s strategy to expand its oncology and bone health portfolio in emerging markets, leveraging its integrated biopharma production chain. No financial terms or launch timelines were disclosed in the announcement.
Timeline
- — Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections (PR Newswire)
- — Innogen Pharmaceuticals Receives PIC/S GMP Certification, Accelerating Global Expansion of Efsubaglutide Alfa (PR Newswire)
- — GMP Biologics Market to Reach US$98.2 Bn by 2033 Accelerates with Biopharmaceutical Innovation (PR Newswire)
Analysis — what this means
Likely next events
- ANVISA product registration submission for denosumab expected within 3–6 months
- Potential commercial launch in Brazil by Q2 2027 if approval follows
- Mabwell may pursue similar GMP inspections in Mexico or Colombia to expand LATAM footprint
Sectors affected
- Biosimilars
- Osteoporosis therapeutics
- Oncology supportive care
- Latin American pharmaceutical markets
Regulatory implications
- PIC/S GMP certification facilitates mutual recognition among 54 participating authorities, reducing duplicative inspections
- ANVISA approval aligns with Brazil’s priority to increase access to affordable biologics
- Ongoing compliance with PIC/S standards required for market maintenance
Historical parallels
- Sandoz’s teriparatide biosimilar approval in Brazil (ANVISA, 2020) enabled first follow-on PTH analog
- Celltrion’s trastuzumab biosimilar gained ANVISA clearance in 2019, launching in Brazil in 2020
- Eli Lilly’s biosimilar efforts in LATAM accelerated after PIC/S-aligned approvals in Brazil (2021–2022)
Key entities
Sources
- Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections — PR Newswire
- Innogen Pharmaceuticals Receives PIC/S GMP Certification, Accelerating Global Expansion of Efsubaglutide Alfa — PR Newswire
- GMP Biologics Market to Reach US$98.2 Bn by 2033 Accelerates with Biopharmaceutical Innovation — PR Newswire